Doxorubicin release

Doxorubicin release" refers to the process by which the anthracycline chemotherapeutic agent doxorubicin is liberated from a drug delivery system (such as nanoparticles, liposomes, beads, or hydrogels) into the biological milieu. The kinetics and extent of drug release depend on carrier composition, environmental conditions, and drug-carrier interactions, which in turn affect therapeutic efficacy and toxicity profiles[2][4][6][8][10]. Release mechanisms are typically governed by physical and chemical properties such as diffusion, dissolution rate, and matrix degradation. This process is a major area of research in pharmaceutical sciences and nanomedicine but does not refer to a molecular target, receptor, or protein. In summary, "Doxorubicin release" should not be classified as a canonical target for drug action, and it is not suitable for structured data collection on targets such as receptors or enzymes. The correct approach is to consider "release" as a process and focus on doxorubicin and its true biological targets, such as DNA, topoisomerase II, and associated biochemical pathways[1][3][5][9].